Assessing gut microbiome's role in predicting inflammatory bowel disease progression
Composition and Metabolic Activity of Gut Microbiota to Predict Early Inflammatory Bowel Disease Progression
This study is trying to see if the types of bacteria in the gut can help predict how inflammatory bowel diseases like Crohn's disease and ulcerative colitis will progress in the first year after diagnosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 140 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Pontificia Universidad Catolica de Chile Academic / other |
| Locations | 1 site (Santiago) |
| Trial ID | NCT06756100 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate how the composition and function of gut microbiota can predict the progression of inflammatory bowel diseases (IBD), specifically Crohn's disease and ulcerative colitis, within the first year after diagnosis. It focuses on identifying biomarkers that could indicate the need for treatment escalation, which is crucial for improving patient outcomes and preventing complications. By analyzing fecal metabolites such as short-chain fatty acids and bile acids, the study seeks to establish a reliable method for guiding timely treatment decisions in IBD patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients experiencing gastrointestinal symptoms such as diarrhea, rectal bleeding, abdominal pain, or urgency for at least three weeks.
Not a fit: Patients with confirmed infectious diseases of the gastrointestinal tract will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with inflammatory bowel disease.
How similar studies have performed: Other studies have indicated the potential of gut microbiota interactions in IBD progression, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with with at least 3 weeks of gastrointestinal symptoms including diarrhea, rectal bleeding, abdominal pain, tenesmus or urgency Exclusion Criteria: * Confirmed infectious disease of the gastrointestinal tract
Where this trial is running
Santiago
- Pontificia Universidad Catolica of Chile — Santiago, Chile (Recruiting)
Study contacts
- Principal investigator: Cristian Hernández-Rocha, MD — Pontificia Universidad Catolica of chile
- Study coordinator: Cristian Hernández-Rocha, MD
- Email: caherna4@uc.cl
- Phone: 56-22-3543822
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.